Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, and Crown CRO, a contract research organization based in Finland, today announced Crown’s engagement to manage Adial’s Phase 3 clinical trial for AD04 for the treatment of alcohol use disorder (AUD). The FDA approved protocol for this Phase 3 clinical trial is a 24-week trial with 290 patients in 30 clinical sites in 5 European countries.
July 6, 2021 Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) announced […]
Dr. Falk Pharma GmbH and Zedira GmbH have announced successful […]
As a Clinical Research Associate CRA you will be joining […]
Each year on the 20th of May, World Clinical Trial […]
Celebrating Easter during a pandemic is certainly hard for us […]